Skip to main content

Advertisement

SpringerLink
Log in

Omalizumab for patients with severe and therapy-refractory atopic eczema?

  • Invited Commentary
  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ring J, Przybilla B, Ruzicka T, eds.: Handbook of Atopic Eczema. New York: Springer; 2006.

    Google Scholar 

  2. Taïeb A, Hanifin J, Cooper K, et al.: Proceedings of the 4th Georg Rajka International Symposium on Atopic Dermatitis, Arcachon, France, September 15–17, 2005. J Allergy Clin Immunol 2006, 117:378–390.

    Article  PubMed  Google Scholar 

  3. Darsow U, Lübbe J, Taïeb A, et al.: for the European Task Force on Atopic Dermatitis: Position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2005, 19:286–295.

    Article  PubMed  CAS  Google Scholar 

  4. Lim A, Luderschmidt S, Weidinger A, et al.: The IgE repertoire in PBMCs of atopic patients is characterized by individual rearrangements without VH bias. J Allergy Clin Immunol 2007, 120:696–706.

    Article  PubMed  CAS  Google Scholar 

  5. Belloni B, Ziai M, Lim A, et al.: Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007, 120:1223–1225.

    PubMed  CAS  Google Scholar 

  6. Lane JE, Cheyney JM, Lane TN, et al.: Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006, 54:68–72.

    Article  PubMed  Google Scholar 

  7. Kakinuma T, Nakamura K, Wakugawa M, et al.: Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol 2001, 107:535–541.

    Article  PubMed  CAS  Google Scholar 

  8. Hijnen D, De Bruin-Weller M, Oosting B, et al.: Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol 2004, 113:334–340.

    Article  PubMed  CAS  Google Scholar 

  9. Kunz B, Oranje AP, Labreze L, et al.: Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997, 195:10–19.

    Article  PubMed  CAS  Google Scholar 

  10. Manz RA, Hauser AE, Hiepe F, Radbruch A: Maintenance of serum antibody levels. Annu Rev Immunol 2005, 23:367–386.

    Article  PubMed  CAS  Google Scholar 

  11. Karnowski A, Achatz-Straussberger G, Klockenbusch C, et al.: Inefficient processing of mRNA for the membrane form of IgE is a genetic mechanism to limit recruitment of IgE-secreting cells. Eur J Immunol 2006, 36:1917–1925.

    Article  PubMed  CAS  Google Scholar 

  12. Deniz YM, Gupta N: Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody. Clin Rev Allergy Immunol 2005, 29:31–48.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology and Allergy, Technical University Munich, Biedersteiner Strasse 29, 80802, Munich, Germany

    Christian Andres

Authors
  1. Christian Andres
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Benedetta Belloni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin Mempel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Johannes Ring
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Andres.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Andres, C., Belloni, B., Mempel, M. et al. Omalizumab for patients with severe and therapy-refractory atopic eczema?. Curr Allergy Asthma Rep 8, 179–180 (2008). https://doi.org/10.1007/s11882-008-0029-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11882-008-0029-3

Keywords

Search

Navigation